Cat. No. 3335
Chemical Name: 5-[1,2-Dihydro-2-oxo-3H-indol-3-yli
Biological ActivityATP-competitive PDGFR, VEGF and FGFR inhibitor (IC50 values are 0.06, 2.43, 3.04 and > 100 μM at PDGFRβ, VEGFR2, FGFR1 and EGFR respectively). Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 values are 0.41, 9.3 and 16.5 μM for VEGF, FGF and PDGF-stimulated growth respectively) and induces > 75% growth inhibition against a broad range of tumor types in vivo. Exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity and is orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Yamamoto et al (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68 9754. PMID: 19047154.
Laird et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60 4152. PMID: 10945623.
Sun et al (1999) Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J.Med.Chem. 42 5120. PMID: 10602697.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SU 6668 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SU 6668, supplier, FGFR, VEGFR, PDGFR, inhibitors, Fibroblast, Growth, Factor, Receptors, Receptor, Tyrosine, Kinases, RTKs, Platelet, Derived, Vascular, Endothelial, KDR, Flt, SU6668, Tocris Bioscience, PDGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitorGW 2580
Selective cFMS kinase inhibitor; orally bioavailable
July 29 - 31, 2016